Modelling trachoma for control programmes

Advances in Experimental Medicine and Biology

Volumn 673, Issue , 2010, Pages 141-156

  Gambhir, Manoj ^a   Basáñez, María Gloria ^b   Blake, Isobel M ^b   Grassly, Nicholas C ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL VIRULENCE; BLINDNESS; CHLAMYDIA TRACHOMATIS; CONVALESCENCE; CORNEA OPACITY; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; ENDEMIC DISEASE; HUMAN; INFECTION CONTROL; INFECTION RATE; INFECTION SENSITIVITY; MATHEMATICAL MODEL; MAXIMUM LIKELIHOOD METHOD; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRACHOMA; AGE; BIOLOGICAL MODEL; REVIEW;

CHLAMYDIA TRACHOMATIS;

AGE FACTORS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BLINDNESS; HUMANS; MODELS, BIOLOGICAL; TRACHOMA;

EID: 77955890996     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6064-1_10     Document Type: Article

References (58)

1. Resnikoff S, Pascolini D, Etya'ale D et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82(11):844-851. (Pubitemid 39573742)
2. Molyneux DH, Hotez PJ, Fenwick A. "Rapid-Impact Interventions": How a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2005; 2(11):e336.
3. West SK, Munoz B, Mkocha H et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: A longitudinal study. Lancet 2005; 366(9493):1296-1300. (Pubitemid 41416585)
4. Burton MJ, Holland MJ, Makalo P et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: A longitudinal study. Lancet 2005; 365(9467):1321-1328.
5. Solomon AW, Holland MJ, Alexander ND et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 351(19):1962-1971. (Pubitemid 39447137)
6. Anderson R, May R. Infectious Diseases of Humans: Dynamics and Control: Oxford University Press; 1992.
7. Bailey R, Duong T, Carpenter R et al. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect 1999; 123(3):479-486. (Pubitemid 30076931)
8. Taylor HR, Johnson SL, Prendergast RA et al. An animal model of trachoma II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci 1982; 23(4):507-515. (Pubitemid 12000565)
9. Grayston JT, Wang SP, Yeh LJ et al. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985; 7(6):717-725.
10. Detels R, Alexander ER, Dhir SP. Trachoma in Punjabi Indians in British Columbia: A prevalence study with comparisons to India. Am J Epidemiol 1966; 84(1):81-91.
11. Baral K, Osaki S, Shreshta B et al. Reliability of clinical diagnosis in identifying infectious trachoma in a low-prevalence area of Nepal. Bull World Health Organ 1999; 77(6):461-466. (Pubitemid 29309653)
12. Hayes LJ, Bailey RL, Mabey DC et al. Genotyping of Chlamydia trachomatis from a trachoma-endemic village in the Gambia by a nested polymerase chain reaction: Identification of strain variants. J Infect Dis 1992; 166(5):1173-1177.
13. Burton MJ, Holland MJ, Faal N et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci 2003; 44(10):4215-4222. (Pubitemid 37186254)
14. Solomon AW, Holland MJ, Burton MJ et al. Strategies for control of trachoma: Observational study with quantitative PCR. Lancet 2003; 362(9379):198-204. (Pubitemid 36859936)
15. Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: What are they really telling us? Lancet Infect Dis 2005; 5(5):313-320. (Pubitemid 40602251)
16. Solomon AW, Peeling RW, Foster A et al. Diagnosis and assessment of trachoma. Clin Microbiol Rev 2004; 17(4):982-1011, table of contents. (Pubitemid 39372527)
17. Miller K, Schmidt G, Melese M et al. How reliable is the clinical exam in detecting ocular chlamydial infection? Ophthalmic Epidemiol 2004; 11(3):255-262. (Pubitemid 39369434)
18. Burton MJ, Holland MJ, Jeffries D et al. Conjunctival chlamydial 16S ribosomal RNA expression in trachoma: Is chlamydial metabolic activity required for disease to develop? Clin Infect Dis 2006; 42(4):463-470. (Pubitemid 43202517)
19. Lansingh VC, Weih LM, Keeffe JE et al. Assessment of trachoma prevalence in a mobile population in Central Australia. Ophthalmic Epidemiol 2001; 8(2-3):97-108. (Pubitemid 32692554)
20. Schemann JF, Sacko D, Banou A et al. [Cartography of trachoma in Mali: Results of a national survey].Bull World Health Organ 1998; 76(6):599-606. (Pubitemid 29143874)
21. Ngondi J, Ole-Sempele F, Onsarigo A et al. Blinding trachoma in postconflict southern Sudan. PLoS Med 2006; 3(12):e478.
22. Ngondi J, Reacher M, Matthews F et al. The epidemiology of low vision and blindness associated with trichiasis in southern Sudan. BMC Ophthalmol 2007; 7:12.
23. Courtright P. Contribution of sex-linked biology and gender roles to disparities with trachoma. Emerg Infect Dis 2004; 10(11):2012-2016. (Pubitemid 39458573)
24. Cumberland P, Hailu G, Todd J. Active trachoma in children aged three to nine years in rural communities in Ethiopia: Prevalence, indicators and risk factors. Trans R Soc Trop Med Hyg 2005; 99(2):120-127. (Pubitemid 40028793)
25. Werner GT, Sareen DK. Trachoma in Punjab: A study of the prevalence and of mass treatment. Trop Geogr Med 1977; 29(2):135-140. (Pubitemid 8189349)
26. Regassa K, Teshome T. Trachoma among adults in Damot Gale District, South Ethiopia. Ophthalmic Epidemiol 2004; 11(1):9-16. (Pubitemid 38367075)
27. Zerihun N. Trachoma in Jimma zone, south western Ethiopia. Trop Med Int Health 1997; 2(12):1115-1121. (Pubitemid 28036024)
28. Ramsey KH, Poulsen CE, Motiu PP. The in vitro antimicrobial capacity of human colostrum against Chlamydia trachomatis. J Reprod Immunol 1998; 38(2):155-167. (Pubitemid 28342651)
29. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: Implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005; 5(2):149-161. (Pubitemid 40208904)
30. Bowman RJ, Jatta B, Cham B et al. Natural history of trachomatous scarring in The Gambia: Results of a 12-year longitudinal follow-up. Ophthalmology 2001; 108(12):2219-2224. (Pubitemid 33100015)
31. West SK, Munoz B, Lynch M et al. Risk factors for constant, severe trachoma among preschool children in Kongwa, Tanzania. Am J Epidemiol 1996; 143(1):73-78. (Pubitemid 26011657)
32. Morrison RP. Chlamydial immunology and vaccinology. Proceedings of the Chlamydia Vaccine Development Colloquium 2003; 19-23.
33. Stephens RS. The cellular paradigm of chlamydial pathogenesis. Trends Microbiol 2003; 11(1):44-51. (Pubitemid 36084355)
34. Ward M, Bailey R, Lesley A et al. Persisting inapparent chlamydial infection in a trachoma endemic community in The Gambia. Scand J Infect Dis Suppl 1990; 69:137-148. (Pubitemid 20333099)
35. West SK, Munoz B, Mkocha H et al. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol 2001; 8(2-3):137-144. (Pubitemid 32692558)
36. Morrison RP. New insights into a persistent problem-chlamydial infections. J Clin Invest 2003; 111(11):1647-1649. (Pubitemid 38057746)
37. Caldwell HD, Wood H, Crane D et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest 2003; 111(11):1757-1769. (Pubitemid 38057756)
38. Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect Immun 2002; 70(6):2741-2751. (Pubitemid 34564127)
39. Mabey DCW, Bailey RL, Hutin YJF. The epidemiology and pathogenesis of trachoma. Review of medical microbiology 1992; 3:112-119.
40. Kumaresan J. Can blinding trachoma be eliminated by 20/20? Eye 2005; 19(10):1067-1073. (Pubitemid 41823765)
41. Lietman T, Porco T, Dawson C et al. Global elimination of trachoma: How frequently should we administer mass chemotherapy? Nat Med 1999; 5(5):572-576. (Pubitemid 29220218)
42. Gill DA, Lakew T, Alemayehu W et al. Complete elimination is a difficult goal for trachoma programs in severely affected communities. Clin Infect Dis 2008; 46(4):564-566. (Pubitemid 351263496)
43. Melese M, Alemayehu W, Lakew T et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008; 299(7):778-784. (Pubitemid 351281571)
44. Ray KJ, Porco TC, Hong KC et al. A rationale for continuing mass antibiotic distributions for trachoma.BMC Infect Dis 2007; 7:91.
45. Melese M, Chidambaram JD, Alemayehu W et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 2004; 292(6):721-725. (Pubitemid 39062527)
46. Solomon AW, Harding-Esch E, Alexander ND et al. Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med 2008; 358(17):1870-1871. (Pubitemid 351581223)
47. Grassly N, Ward ME, Ferris S et al. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Neglected Tropical Diseases 2008; 2(12): E341.
48. Boas ML. Mathematical Methods In The Physical Sciences. 2nd ed. New York: John Wiley & Sons, 1983
49. Gambhir M, Basanez MG, Turner F et al. Trachoma: Transmission, infection and control. Lancet Infect Dis 2007; 7(6):420-427.
50. WHO. WHO Statistical Information System (WHOSIS); http://www3.who.int/ whosis/menu.cfm?path?whosis,life.
51. West ES, Munoz B, Mkocha H et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci 2005; 46(1):83-87. (Pubitemid 40041182)
52. West SK, Munoz B, Mkocha H et al. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest Ophthalmol Vis Sci 2007; 48(4):1492-1497. (Pubitemid 351261330)
53. Schachter J, West SK, Mabey D et al. Azithromycin in control of trachoma. Lancet 1999; 354(9179):630-635. (Pubitemid 29391427)
54. Bailey RL, Arullendran P, Whittle HC et al. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993; 342(8869):453-456. (Pubitemid 23240308)
55. Michel CE, Solomon AW, Magbanua JP et al. Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: A comparative study. Lancet 2006; 367(9522):1585-1590.
56. Taylor HR. Trachoma grading: A new grading scheme. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 1987(64):175-181.
57. Gambhir M, Basánez M-G, Burton MJ et al. The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control. PLoS Neg Trop Dis, doi:10:1371/journal, pntd.0000462, 2009.
58. Blake IM, Burton MJ, Bailey RL et al. Estimating household and community transmission of ocular Chlamydia trachomatis. PLoS Neglected Tropical Diseases 2009, 3(3): E401.